{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:21:01Z","timestamp":1782145261040,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["20167781"],"award-info":[{"award-number":["20167781"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","award":["FP7-CP-FP506 2007 (grant agreement no. 222915)"],"award-info":[{"award-number":["FP7-CP-FP506 2007 (grant agreement no. 222915)"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Aim of this study was to evaluate the relationship of plasma PCSK9 with metabolic and inflammatory profile and coronary atherosclerotic burden in patients with suspected CAD enrolled in the EVINCI study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PCSK9 was measured in 539 patients (60.3\u2009\u00b1\u20098.6\u00a0years, 256 males) with symptoms of CAD characterized by risk factors, bio-humoral profiles, and treatment. N\u2009=\u2009412 patients underwent coronary computed tomography angiography (CTA) to assess the presence and characteristics of coronary atherosclerosis. A CTA score, combining extent, severity, composition, and location of plaques was computed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients were divided according to PCSK9 quartiles: I (&lt;\u2009136\u00a0ng\/mL), II\u2013III (136\u2013266\u00a0ng\/mL), and IV quartile (&gt;\u2009266\u00a0ng\/mL). Compared with patients in quartile IV, patients in quartile I had a higher prevalence of the metabolic syndrome and higher values of body mass index. LDL- and HDL-cholesterol were significantly lower in patients in the quartile I than in those in quartile IV. Coronary CTA documented normal vessels in 30% and obstructive CAD in 35% of cases without differences among PCSK9 quartiles. Compared with patients with the highest levels, patients with the lowest PCSK9 levels had a higher CTA score mainly due to higher number of mixed non-obstructive coronary plaques. At multivariable analysis including clinical, medications, and lipid variables, PCSK9 was an independent predictor of the CTA score (coefficient \u2212\u20090.129, SE 0.03, P\u2009&lt;\u20090.0001), together with age, male gender, statins, interleukin-6, and leptin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In patients with stable CAD, low PCSK9 plasma levels are associated with a particular metabolic phenotype (low HDL cholesterol, the metabolic syndrome, obesity, insulin resistance and diabetes) and diffuse non-obstructive coronary atherosclerosis.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov NCT00979199. Registered September 17, 2009<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0949-3","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T13:04:39Z","timestamp":1572527079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct00979199","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-2460","authenticated-orcid":false,"given":"Chiara","family":"Caselli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Del Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosetta","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Lorenzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"De Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Basta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Scholte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Neglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"issue":"1","key":"949_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","volume":"70","author":"GA Roth","year":"2017","unstructured":"Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1\u201325.","journal-title":"J Am Coll Cardiol"},{"issue":"9493","key":"949_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists\u2019 (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet"},{"issue":"36","key":"949_CR3","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/eurheartj\/ehv174","volume":"36","author":"YJ Shimada","year":"2015","unstructured":"Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin\/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36(36):2415\u201324.","journal-title":"Eur Heart J"},{"issue":"5","key":"949_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/humu.9383","volume":"26","author":"D Allard","year":"2005","unstructured":"Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich A, Junien C, Varret M, Boileau C, Benlian P, Rab\u00e8s JP. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat. 2005;26(5):497.","journal-title":"Hum Mutat"},{"issue":"12","key":"949_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372.","journal-title":"N Engl J Med"},{"issue":"5","key":"949_CR6","doi-asserted-by":"publisher","first-page":"e001992","DOI":"10.1161\/CIRCGEN.117.001992","volume":"11","author":"J Pott","year":"2018","unstructured":"Pott J, Schlegel V, Teren A, Horn K, Kirsten H, Bluecher C, Kratzsch J, Loeffler M, Thiery J, Burkhardt R, Scholz M. Genetic regulation of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) plasma levels and its impact on atherosclerotic vascular disease phenotypes. Circ Genom Precis Med. 2018;11(5):e001992.","journal-title":"Circ Genom Precis Med."},{"issue":"6","key":"949_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.diabet.2017.07.009","volume":"43","author":"B Cariou","year":"2017","unstructured":"Cariou B, Gu\u00e9rin P, Le May C, Letocart V, Arnaud L, Guyomarch B, Pichelin M, Probst V. Circulating PCSK9 levels in acute coronary syndrome: results from the PC-SCA-9 prospective study. Diabetes Metab. 2017;43(6):529\u201335.","journal-title":"Diabetes Metab."},{"issue":"3","key":"949_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4093\/dmj.2017.0081","volume":"42","author":"KH Bae","year":"2018","unstructured":"Bae KH, Kim SW, Choi YK, Seo JB, Kim N, Kim CY, Lee WK, Lee S, Kim JG, Lee IK, Lee JH, Park KG. Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome. Diabetes Metab J. 2018;42(3):207\u201314.","journal-title":"Diabetes Metab J."},{"key":"949_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","volume":"248","author":"JM Cheng","year":"2016","unstructured":"Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Boersma E, van Geuns RJ, Serruys PW, Kardys I, Akkerhuis KM. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016;248:117\u201322.","journal-title":"Atherosclerosis."},{"issue":"9","key":"949_CR10","doi-asserted-by":"publisher","first-page":"e106294","DOI":"10.1371\/journal.pone.0106294","volume":"2","author":"NA Almontashiri","year":"2014","unstructured":"Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi AA, Chen HH, Stewart AF. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS ONE. 2014;2(9):e106294.","journal-title":"PLoS ONE"},{"issue":"10","key":"949_CR11","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","volume":"35","author":"YM Zhu","year":"2015","unstructured":"Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, Verma S. Association of proprotein convertase subtilisin\/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention. Arterioscler Thromb Vasc Biol. 2015;35(10):2254\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"949_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00380-018-1218-1","volume":"34","author":"D Nose","year":"2019","unstructured":"Nose D, Shiga Y, Ueda Y, Idemoto Y, Tashiro K, Suematsu Y, Kuwano T, Kitajima K, Saku K, Miura SI. Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese. Heart Vessels. 2019;34(1):19\u201328.","journal-title":"Heart Vessels"},{"issue":"5","key":"949_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.hlc.2015.10.017","volume":"25","author":"DC Chan","year":"2016","unstructured":"Chan DC, Pang J, McQuillan BM, Hung J, Beilby JP, Barrett PH, Watts GF. Plasma proprotein convertase subtilisin kexin type 9 as a predictor of carotid atherosclerosis in asymptomatic adults. Heart Lung Circ. 2016;25(5):520\u20135.","journal-title":"Heart Lung Circ."},{"issue":"6","key":"949_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.metabol.2013.01.005","volume":"62","author":"CJ Lee","year":"2013","unstructured":"Lee CJ, Lee YH, Park SW, Kim KJ, Park S, Youn JC, Lee SH, Kang SM, Jang Y. Association of serum proprotein convertase subtilisin\/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism. 2013;62(6):845\u201350.","journal-title":"Metabolism."},{"issue":"2","key":"949_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40119-017-0092-8","volume":"6","author":"\u0160 T\u00f3th","year":"2017","unstructured":"T\u00f3th \u0160, Feda\u010dko J, Pek\u00e1rov\u00e1 T, Hertelyov\u00e1 Z, Katz M, Mughees A, Kuzma J, \u0160tefani\u010d P, Kopolovets I, Pella D. Elevated circulating PCSK9 concentrations predict subclinical atherosclerotic changes in low risk obese and non-obese patients. Cardiol Ther. 2017;6(2):281\u20139.","journal-title":"Cardiol Ther."},{"key":"949_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.atherosclerosis.2016.08.038","volume":"254","author":"R Alonso","year":"2016","unstructured":"Alonso R, Mata P, Mu\u00f1iz O, Fuentes-Jimenez F, D\u00edaz JL, Zamb\u00f3n D, Tom\u00e1s M, Martin C, Moyon T, Croyal M, Thedrez A, Lambert G. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis. 2016;254:249\u201353.","journal-title":"Atherosclerosis."},{"issue":"1","key":"949_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/0004563217695351","volume":"55","author":"X Zhao","year":"2018","unstructured":"Zhao X, Zhang HW, Li S, Zhang Y, Xu RX, Zhu CG, Wu NQ, Guo YL, Qing P, Li XL, Liu G, Dong Q, Sun J, Li JJ. Association between plasma proprotein convertase subtisilin\/kexin type 9 concentration and coronary artery calcification. Ann Clin Biochem. 2018;55(1):158\u201364.","journal-title":"Ann Clin Biochem"},{"issue":"10","key":"949_CR18","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","volume":"122","author":"MD Shapiro","year":"2018","unstructured":"Shapiro MD, Tavori H, Fazio S. PCSK9: from basic science discoveries to clinical trials. Circ Res. 2018;122(10):1420\u201338.","journal-title":"Circ Res"},{"issue":"1","key":"949_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrcardio.2016.166","volume":"14","author":"G Pasterkamp","year":"2017","unstructured":"Pasterkamp G, den Ruijter HM, Libby P. Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. Nat Rev Cardiol. 2017;14(1):21\u20139.","journal-title":"Nat Rev Cardiol."},{"key":"949_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"1","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokg\u00f6zo\u011flu L, Lewis EF. Atherosclerosis. Nat Rev Dis Primers. 2019;1:56.","journal-title":"Nat Rev Dis Primers."},{"key":"949_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/CIRCIMAGING.114.002179","volume":"8","author":"D Neglia","year":"2015","unstructured":"Neglia D, Rovai D, Caselli C, EVINCI Study Investigators, et al. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging. 2015;8:3.","journal-title":"Circ Cardiovasc Imaging."},{"issue":"4","key":"949_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.amjcard.2015.05.008","volume":"116","author":"D Rovai","year":"2015","unstructured":"Rovai D, Neglia D, Lorenzoni V, Caselli C, Knuuti J, Underwood SR, EVINCI Study Investigators. Limitations of chest pain categorization models to predict coronary artery disease. Am J Cardiol. 2015;116(4):504\u20137.","journal-title":"Am J Cardiol."},{"issue":"1","key":"949_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2015.04.811","volume":"241","author":"C Caselli","year":"2015","unstructured":"Caselli C, De Graaf MA, Lorenzoni V, Rovai D, Marinelli M, Del Ry S, Giannessi D, Bax JJ, Neglia D, Scholte AJ. HDL cholesterol, leptin and interleukin-6 predict high risk coronary anatomy assessed by CT angiography in patients with stable chest pain. Atherosclerosis. 2015;241(1):55\u201361.","journal-title":"Atherosclerosis."},{"issue":"6","key":"949_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cjca.2015.01.035","volume":"31","author":"C Caselli","year":"2015","unstructured":"Caselli C, Rovai D, Lorenzoni V, EVINCI Study Investigators, et al. A new integrated clinical-biohumoral model to predict functionally significant coronary artery disease in patients with chronic chest pain. Can J Cardiol. 2015;31(6):709\u201316.","journal-title":"Can J Cardiol."},{"issue":"4","key":"949_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1161\/ATVBAHA.115.306818","volume":"36","author":"C Caselli","year":"2016","unstructured":"Caselli C, Prontera C, Liga R, et al. Effect of coronary atherosclerosis and myocardial ischemia on plasma levels of high-sensitivity troponin T and NT-proBNP in patients with stable angina. Arterioscler Thromb Vasc Biol. 2016;36(4):757\u201364.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"949_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/ehjci\/jew038","volume":"17","author":"R Liga","year":"2016","unstructured":"Liga R, Vontobel J, Rovai D, EVINCI Study Investigators, et al. Multicentre multi-device hybrid imaging study of coronary artery disease: results from the EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of Ischaemic Heart Disease (EVINCI) hybrid imaging population. Eur Heart J Cardiovasc Imaging. 2016;17(9):951\u201360.","journal-title":"Eur Heart J Cardiovasc Imaging."},{"issue":"12","key":"949_CR27","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/j.amjcard.2014.03.034","volume":"113","author":"MA de Graaf","year":"2014","unstructured":"de Graaf MA, Broersen A, Ahmed W, Kitslaar PH, Dijkstra J, Kroft LJ, Delgado V, Bax JJ, Reiber JH, Scholte AJ. Feasibility of an automated quantitative computed tomography angiography-derived risk score for risk stratification of patients with suspected coronary artery disease. Am J Cardiol. 2014;113(12):1947\u201355.","journal-title":"Am J Cardiol"},{"key":"949_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.10.024","author":"AR van Rosendael","year":"2019","unstructured":"van Rosendael AR, Shaw LJ, Xie JX, et al. Superior risk stratification with coronary computed tomography angiography using a comprehensive atherosclerotic risk score. JACC Cardiovasc Imaging. 2019. https:\/\/doi.org\/10.1016\/j.jcmg.2018.10.024.","journal-title":"JACC Cardiovasc Imaging."},{"issue":"7","key":"949_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412\u20139.","journal-title":"Diabetologia"},{"key":"949_CR30","volume-title":"Obesity preventing and managing the global epidemic. Report of a WHO Consultation","author":"WHO","year":"2000","unstructured":"WHO. Obesity preventing and managing the global epidemic. Report of a WHO Consultation. Geneva: World Health Organization; 2000."},{"issue":"17","key":"949_CR31","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735\u201352.","journal-title":"Circulation."},{"issue":"9491","key":"949_CR32","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"366","author":"KG Alberti","year":"2005","unstructured":"Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome\u2014a new worldwide definition. Lancet. 2005;366(9491):1059\u201362.","journal-title":"Lancet."},{"issue":"6","key":"949_CR33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"issue":"1","key":"949_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1074248417724868","volume":"23","author":"TD Filippatos","year":"2018","unstructured":"Filippatos TD, Kei A, Rizos CV, Elisaf MS. Effects of PCSK9 inhibitors on other than low-density lipoprotein cholesterol lipid variables. J Cardiovasc Pharmacol Ther. 2018;23(1):3\u201312.","journal-title":"J Cardiovasc Pharmacol Ther."},{"issue":"7","key":"949_CR35","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/jc.2009-0141","volume":"94","author":"SG Lakoski","year":"2009","unstructured":"Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"949_CR36","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2010.09.027","volume":"213","author":"Q Cui","year":"2010","unstructured":"Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, Hu Y, Haas JV, Troutt JS, Pickard RT, Darling R, Konrad RJ, Zhou H, Cao G. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis. 2010;213(2):632\u20136.","journal-title":"Atherosclerosis."},{"issue":"1","key":"949_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","volume":"51","author":"G Dubuc","year":"2010","unstructured":"Dubuc G, Tremblay M, Par\u00e9 G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, Davignon J. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010;51(1):140\u20139.","journal-title":"J Lipid Res"},{"key":"949_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.004","volume":"173","author":"N Ferri","year":"2016","unstructured":"Ferri N, Corsini A, Macchi C, Magni P, Ruscica M. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Transl Res. 2016;173:19\u201329.","journal-title":"Transl Res."},{"issue":"12","key":"949_CR39","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.amjcard.2004.02.058","volume":"93","author":"RG Victor","year":"2004","unstructured":"Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, Basit M, Cooper RS, Iannacchione VG, Visscher WA, Staab JM, Hobbs HH, Dallas Heart Study Investigators. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004;93(12):1473\u201380.","journal-title":"Am J Cardiol."},{"issue":"2","key":"949_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2012.04.006","volume":"223","author":"M Abifadel","year":"2012","unstructured":"Abifadel M, Guerin M, Benjannet S, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis. 2012;223(2):394\u2013400.","journal-title":"Atherosclerosis."},{"key":"949_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1476-511X-10-5","volume":"10","author":"LH Aung","year":"2011","unstructured":"Aung LH, Yin RX, Miao L, Hu XJ, Yan TT, Cao XL, Wu DF, Li Q, Pan SL, Wu JZ. The proprotein convertase subtilisin\/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis. 2011;10:5.","journal-title":"Lipids Health Dis."},{"issue":"2","key":"949_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","volume":"62","author":"C Werner","year":"2014","unstructured":"Werner C, Hoffmann MM, Winkler K, B\u00f6hm M, Laufs U. Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol. 2014;62(2):94\u2013102.","journal-title":"Vascul Pharmacol"},{"issue":"2","key":"949_CR43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","volume":"49","author":"HE Careskey","year":"2008","unstructured":"Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9. J Lipid Res. 2008;49(2):394\u20138.","journal-title":"J Lipid Res"},{"issue":"7","key":"949_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-511X-7-22","volume":"11","author":"J Mayne","year":"2008","unstructured":"Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chr\u00e9tien M. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008;11(7):22.","journal-title":"Lipids Health Dis."},{"issue":"2","key":"949_CR45","doi-asserted-by":"publisher","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","volume":"2","author":"F Raal","year":"2013","unstructured":"Raal F, Panz V, Immelman A, Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013;2(2):e000028.","journal-title":"J Am Heart Assoc."},{"issue":"3","key":"949_CR46","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s12020-016-0939-0","volume":"54","author":"N Ferri","year":"2016","unstructured":"Ferri N, Ruscica M. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine. 2016;54(3):588\u2013601.","journal-title":"Endocrine"},{"issue":"12","key":"949_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.clinbiochem.2014.03.022","volume":"47","author":"Z Awan","year":"2014","unstructured":"Awan Z, Dubuc G, Faraj M, Dufour R, Seidah NG, Davignon J, Rabasa-Lhoret R, Baass A. The effect of insulin on circulating PCSK9 in postmenopausal obese women. Clin Biochem. 2014;47(12):1033\u20139.","journal-title":"Clin Biochem"},{"issue":"22","key":"949_CR48","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144\u201353.","journal-title":"N Engl J Med"},{"issue":"2","key":"949_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","volume":"5","author":"AF Schmidt","year":"2017","unstructured":"Schmidt AF, Swerdlow DI, Holmes MV, et al. UCLEB consortium, Sattar N. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2017;5(2):97\u2013105.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"13","key":"949_CR50","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316(13):1383\u201391.","journal-title":"JAMA"},{"issue":"1","key":"949_CR51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12933-018-0689-9","volume":"17","author":"SH Yang","year":"2018","unstructured":"Yang SH, Xu RX, Cui CJ, Wang Y, Du Y, Chen ZG, Yao YH, Ma CY, Zhu CG, Guo YL, Wu NQ, Sun J, Chen BX, Li JJ. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db\/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol. 2018;17(1):48.","journal-title":"Cardiovasc Diabetol."},{"issue":"2","key":"949_CR52","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2337\/dc17-1464","volume":"41","author":"LSF de Carvalho","year":"2018","unstructured":"de Carvalho LSF, Campos AM, Sposito AC. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care. 2018;41(2):364\u20137.","journal-title":"Diabetes Care"},{"issue":"6","key":"949_CR53","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jacl.2015.08.005","volume":"9","author":"YGL Saavedra","year":"2015","unstructured":"Saavedra YGL, Dufour R, Baass A. Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes\/diabetes risk. J Clin Lipidol. 2015;9(6):786\u201393.","journal-title":"J Clin Lipidol."},{"issue":"8","key":"949_CR54","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cjca.2013.03.004","volume":"29","author":"Z Awan","year":"2013","unstructured":"Awan Z, Delvin EE, Levy E, Genest J, Davignon J, Seidah NG, Baass A. Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype. Can J Cardiol. 2013;29(8):927\u201333.","journal-title":"Can J Cardiol"},{"issue":"1","key":"949_CR55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","volume":"16","author":"E Paige","year":"2017","unstructured":"Paige E, Masconi KL, Tsimikas S, Kronenberg F, Santer P, Weger S, Willeit J, Kiechl S, Willeit P. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16(1):38.","journal-title":"Cardiovasc Diabetol."},{"key":"949_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-019-09879-0","author":"M Satish","year":"2019","unstructured":"Satish M, Saxena SK, Agrawal DK. Adipokine dysregulation and insulin resistance with atherosclerotic vascular disease: metabolic syndrome or independent sequelae? J Cardiovasc Transl Res. 2019. https:\/\/doi.org\/10.1007\/s12265-019-09879-0.","journal-title":"J Cardiovasc Transl Res."},{"issue":"5","key":"949_CR57","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","volume":"48","author":"M Ruscica","year":"2016","unstructured":"Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C, Maggioni M, Fracanzani AL, Badiali S, Fargion S, Magni P, Valenti L, Dongiovanni P. Liver fat accumulation is associated with circulating PCSK9. Ann Med. 2016;48(5):384\u201391.","journal-title":"Ann Med"},{"issue":"9","key":"949_CR58","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","volume":"55","author":"A Baass","year":"2009","unstructured":"Baass A, Dubuc G, Tremblay M, Delvin EE, O\u2019Loughlin J, Levy E, Davignon J, Lambert M. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009;55(9):1637\u201345.","journal-title":"Clin Chem"},{"key":"949_CR59","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3748\/wjg.v21.i3.711","volume":"3","author":"S Sookoian","year":"2015","unstructured":"Sookoian S, Pirola CJ. Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine. World J Gastroenterol. 2015;3:711\u201325.","journal-title":"World J Gastroenterol"},{"key":"949_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319862401","author":"R Quispe","year":"2019","unstructured":"Quispe R, Elshazly MB, Zhao D, Toth PP, Puri R, Virani SS, Blumenthal RS, Martin SS, Jones SR, Michos ED. Total cholesterol\/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: the ARIC study. Eur J Prev Cardiol. 2019. https:\/\/doi.org\/10.1177\/2047487319862401.","journal-title":"Eur J Prev Cardiol."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-019-0949-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:16:27Z","timestamp":1628612187000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0949-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["949"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0949-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"11 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics Committee approval was provided by each European EVINCI center and all subjects provided written informed consent. A specific approval from Ethics Committee \u201cArea Vasta Nord Ovest per la Sperimentazione Clinica\u201d was provided for this study (Protocol N. 2673, 2017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}